NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Impact · against what's priced in

Alnylam faces significant downward pressure following a $200 million revenue guidance cut for its TTR product and a subsequent 28% share price collapse. The initiation of a securities law investigation by Kessler Topaz adds a layer of long-term legal risk to an already distressed valuation.

ALNY−0.80

No priced-in read yet